Company

Tasly Pharma Partners with Beijing Neurosurgical Institute on Dual-Target CAR-T Therapy – RMB 240M Investment Advances CD44/CD133 Autologous Treatment for Recurrent Glioblastoma

Tasly Pharma Co., Ltd (SHA: 600535) announced plans to enter a collaboration agreement with the...

Mannerchem Secures Exclusive China Rights to Kintor’s AI-Discovered Whitening Ingredient Oximidol KT-939

Fineline Cube Apr 14, 2026

Mannerchem, the China-based specialty chemicals company, has formed a strategic partnership with domestic biopharmaceutical firm...

Company Drug

Youcare Pharmaceutical Advances Dual mRNA Vaccine Pipeline with NMPA Approvals for RSV and Herpes Zoster Candidates

Fineline Cube Apr 14, 2026

Youcare Pharmaceutical Group (SHA: 688658) announced separate clinical trial approvals from China’s National Medical Products...

Company Deals

GlycoNex and Nippon Kayaku Collaborate on Next-Generation Protease-Activated ADC GNX201 for Solid Tumors

Fineline Cube Apr 14, 2026

GlycoNex, Inc. announced on March 23, 2026, a strategic collaboration agreement with Nippon Kayaku Co.,...

Company Deals

Harbin Gloria Pharmaceuticals Acquires Neurodegenerative Disease Candidate from Capital Medical University for RMB 14.15M

Fineline Cube Apr 14, 2026

Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437) announced the signing of a technology transfer agreement...

Company Deals

Menarini Group Partners with Shanghai Angel Baby Foundation on Three-Year Pediatric Scar Care Initiative – Dermatix Ultra Gel Expertise Extended to Public Welfare Collaboration

Fineline Cube Apr 14, 2026

Menarini Group, the Italian pharmaceutical company, and the Shanghai Angel Baby Charity Foundation have officially...

Company Drug

Eli Lilly’s Jaypirca Combination Therapy Demonstrates Significant PFS Benefit in Phase III CLL/SLL Trial – Non-Covalent BTK Inhibitor Shows Promise Regardless of Prior Treatment History

Fineline Cube Apr 14, 2026

Eli Lilly and Company (NYSE: LLY) announced positive topline results from the Phase III BRUIN...

Company Drug

Sanofi Secures EC Approval for Dupixent in Pediatric Chronic Spontaneous Urticaria – First Biologic Therapy for Children 2–11 Years

Fineline Cube Apr 14, 2026

Sanofi SA (NASDAQ: SNY) announced that the European Commission (EC) has granted marketing authorization for...

Company Drug

AstraZeneca’s Imjudo Gains NMPA Approval for First-Line NSCLC in China, Backed by POSEIDON Data

Fineline Cube Apr 13, 2026

AstraZeneca plc (NYSE: AZN) has secured marketing approval from China’s National Medical Products Administration (NMPA)...

Company Drug

RemeGen’s Disitamab Vedotin Wins World’s First HER2-ADC Approval for First-Line Advanced Urothelial Carcinoma

Fineline Cube Apr 13, 2026

RemeGen Ltd. (HKG: 9995) has announced that China’s National Medical Products Administration (NMPA) has approved...

Company Drug

Henlius Biotech Doses First Patient in Phase I Trial for HLX319, a Biosimilar to Roche’s Phesgo

Fineline Cube Apr 13, 2026

Shanghai Henlius Biotech, Inc. (HKG: 2696) has announced the dosing of the first subject in...

Company Drug

AbbVie Secures NMPA Label Expansion for Rinvoq in China, Clarifying Use in UC and Crohn’s Disease

Fineline Cube Apr 13, 2026

AbbVie Inc. (NYSE: ABBV) has announced that China’s National Medical Products Administration (NMPA) has approved...

Company Deals

IASO Biotherapeutics Partners with Brazil’s Butantan Institute to Localize CAR-T Therapy for Hematological Cancers

Fineline Cube Apr 13, 2026

IASO Biotherapeutics, a Chinese cell therapy innovator, has entered into a strategic technology collaboration and...

Company Drug

CanSino Biologics Secures NMPA Approval for Pankangxin, China’s First Three-Component Acellular DTaP Vaccine

Fineline Cube Apr 13, 2026

CanSino Biologics Inc. (HKG: 6185) has announced that China’s National Medical Products Administration (NMPA) has...

Company Deals

Zhejiang Medicine Plans HKEX Spin-Off of NovoCodex Biopharmaceuticals to Unlock ADC Pipeline Value

Fineline Cube Apr 13, 2026

Zhejiang Medicine Co., Ltd. (SHA: 600216) has announced its strategic intention to spin off its...

Company Drug

Cutia Therapeutics’ CU-20101 Meets Phase III Endpoints, Demonstrating Non-Inferiority to BOTOX for Glabellar Lines

Fineline Cube Apr 13, 2026

Cutia Therapeutics (HKG: 2487) has announced the successful completion of its pivotal Phase III clinical...

Company Drug

Hotgen Biotech’s Novel Treg-Targeting Bispecific Antibody SGT003 Clears NMPA Filing Hurdle

Fineline Cube Apr 13, 2026

Hotgen Biotech Co., Ltd. (SHA: 688068) has announced that the National Medical Products Administration (NMPA)...

Company Deals

Haisco Pharma Licenses Nav1.8 Pain Program to AbbVie in $745M Deal, Retaining Greater China Rights

Fineline Cube Apr 13, 2026

Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) has entered into a strategic exclusive licensing agreement...

Company Drug

FDA Accepts NDA for Telix’s Pixclara (TLX101-Px) Glioma Imaging Agent, Decision Expected September 2026

Fineline Cube Apr 13, 2026

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX), the Australian partner of Grand Pharmaceutical Group Co.,...

Company Drug

GSK’s B7-H4 ADC Mocertatug Rezetecan Shows 62-67% Response Rates in Phase I Ovarian and Endometrial Cancer Trials

Fineline Cube Apr 13, 2026

GlaxoSmithKline plc (GSK, NYSE: GSK) has reported highly promising data from the global Phase I...

Company

Tasly Pharma Partners with Beijing Neurosurgical Institute on Dual-Target CAR-T Therapy – RMB 240M Investment Advances CD44/CD133 Autologous Treatment for Recurrent Glioblastoma

Mannerchem Secures Exclusive China Rights to Kintor’s AI-Discovered Whitening Ingredient Oximidol KT-939

Youcare Pharmaceutical Advances Dual mRNA Vaccine Pipeline with NMPA Approvals for RSV and Herpes Zoster Candidates

GlycoNex and Nippon Kayaku Collaborate on Next-Generation Protease-Activated ADC GNX201 for Solid Tumors

Harbin Gloria Pharmaceuticals Acquires Neurodegenerative Disease Candidate from Capital Medical University for RMB 14.15M

Menarini Group Partners with Shanghai Angel Baby Foundation on Three-Year Pediatric Scar Care Initiative – Dermatix Ultra Gel Expertise Extended to Public Welfare Collaboration

Eli Lilly’s Jaypirca Combination Therapy Demonstrates Significant PFS Benefit in Phase III CLL/SLL Trial – Non-Covalent BTK Inhibitor Shows Promise Regardless of Prior Treatment History

Sanofi Secures EC Approval for Dupixent in Pediatric Chronic Spontaneous Urticaria – First Biologic Therapy for Children 2–11 Years

AstraZeneca’s Imjudo Gains NMPA Approval for First-Line NSCLC in China, Backed by POSEIDON Data

RemeGen’s Disitamab Vedotin Wins World’s First HER2-ADC Approval for First-Line Advanced Urothelial Carcinoma

Henlius Biotech Doses First Patient in Phase I Trial for HLX319, a Biosimilar to Roche’s Phesgo

AbbVie Secures NMPA Label Expansion for Rinvoq in China, Clarifying Use in UC and Crohn’s Disease

IASO Biotherapeutics Partners with Brazil’s Butantan Institute to Localize CAR-T Therapy for Hematological Cancers

CanSino Biologics Secures NMPA Approval for Pankangxin, China’s First Three-Component Acellular DTaP Vaccine

Zhejiang Medicine Plans HKEX Spin-Off of NovoCodex Biopharmaceuticals to Unlock ADC Pipeline Value

Cutia Therapeutics’ CU-20101 Meets Phase III Endpoints, Demonstrating Non-Inferiority to BOTOX for Glabellar Lines

Hotgen Biotech’s Novel Treg-Targeting Bispecific Antibody SGT003 Clears NMPA Filing Hurdle

Haisco Pharma Licenses Nav1.8 Pain Program to AbbVie in $745M Deal, Retaining Greater China Rights

FDA Accepts NDA for Telix’s Pixclara (TLX101-Px) Glioma Imaging Agent, Decision Expected September 2026

GSK’s B7-H4 ADC Mocertatug Rezetecan Shows 62-67% Response Rates in Phase I Ovarian and Endometrial Cancer Trials

You Missed

AbbVie Partners with Santen China for Exclusive Distribution of Five Glaucoma Franchise Products

Annoroad Gene Technology Files for Hong Kong IPO to Capitalize on Integrated Molecular Diagnostics Platform

Mabwell Bioscience Expands Southeast Asia Reach with Malaysian Licensing Deal for Denosumab Biosimilars Rexeva and Denosu

Sunshine Lake Pharma Secures NMPA Approval for In-House Developed Premixed Insulin 30R Prefilled Pen